Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 02 2022
28 02 2022
Historique:
received:
20
07
2021
accepted:
11
02
2022
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Intraoperative parathyroid hormone dosage allows real-time monitoring of the decrease in PTH levels during parathyroidectomy and verify procedure's efficacy. Currently, none of the interpretative criteria used has absolute accuracy. The aim of this study is to evaluate diagnostic accuracy of the Rome criterion verifying diagnostic significance of the individual assays. A total of 205 patients with primary hyperparathyroidism from a single adenoma were retrospectively evaluated and monitored with baseline PTH, PTH at 10 min and PTH at 20 min after adenoma excision. The accuracy of the latter two assays compared with baseline was compared by ROC curves. In addition, was evaluated the influence on these data of localization diagnostics (ultrasounds and scintigraphy), definitive histology, and type of surgery performed. The ratio of 20-min sampling to baseline in the Rome criterion showed highest diagnostic significance. This finding was not influenced by the type of surgery performed, definitive histologic examination, or intraoperative localization of the adenoma. The Rome criterion has shown its high reliability in detecting persistence. The ratio of sampling at 20 min to baseline is by far the best performing. Further studies are needed to evaluate whether sampling at 10 min after adenoma excision can be considered not mandatory.
Identifiants
pubmed: 35228624
doi: 10.1038/s41598-022-07380-4
pii: 10.1038/s41598-022-07380-4
pmc: PMC8885714
doi:
Substances chimiques
Parathyroid Hormone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3333Informations de copyright
© 2022. The Author(s).
Références
Langenbecks Arch Surg. 2019 Dec;404(8):919-927
pubmed: 31595330
Am J Otolaryngol. 2021 Jan - Feb;42(1):102819
pubmed: 33157312
Am J Surg. 1994 Nov;168(5):466-8
pubmed: 7977975
Isr Med Assoc J. 2003 Nov;5(11):775-7
pubmed: 14650100
Br J Surg. 2021 Jun 22;108(6):675-683
pubmed: 34157082
J Clin Med. 2020 Nov 02;9(11):
pubmed: 33147842
Surgery. 2003 Dec;134(6):973-9; discussion 979-81
pubmed: 14668730
Surgery. 2019 Jul;166(1):50-54
pubmed: 30975497
Head Neck. 2018 Dec;40(12):2664-2669
pubmed: 30479056
Langenbecks Arch Surg. 2009 Sep;394(5):843-9
pubmed: 19529957
Head Neck. 2017 Feb;39(2):241-246
pubmed: 27557453
World J Surg. 2021 Jul;45(7):2148-2154
pubmed: 33738523
World J Surg. 2008 Nov;32(11):2509-15
pubmed: 18758853
Surgery. 2018 Jan;163(1):42-47
pubmed: 29128188
Surgery. 2006 Dec;140(6):883-9; discussion 889-90
pubmed: 17188134
Langenbecks Arch Surg. 2018 Feb;403(1):103-109
pubmed: 29294178
Clin Biochem. 2007 Jun;40(9-10):595-603
pubmed: 17349989
Case Rep Oncol. 2017 Dec 11;10(3):1105-1111
pubmed: 29430234
Otolaryngol Head Neck Surg. 2018 May;158(5):828-834
pubmed: 29436275
Surgery. 1988 Dec;104(6):1121-7
pubmed: 3194839
Endocr Pract. 2018 Jun;24(6):589-598
pubmed: 29949431
G Chir. 2019 Sep-Oct;40(5):389-397
pubmed: 32003717
G Chir. 2016 May-Jun;37(3):123-129
pubmed: 27734796
Surgery. 1999 Dec;126(6):1139-43; discussion 1143-4
pubmed: 10598199
Int J Surg. 2016 Jan;25:49-53
pubmed: 26639086
Surgery. 2007 Sep;142(3):398-404
pubmed: 17723893
J Clin Endocrinol Metab. 2002 Mar;87(3):1024-9
pubmed: 11889156
J Endocrinol Invest. 2020 Sep;43(9):1205-1212
pubmed: 32124267
Langenbecks Arch Surg. 2008 Sep;393(5):639-45
pubmed: 18651167
J Endocrinol Invest. 2018 Nov;41(11):1339-1348
pubmed: 29616419
Surgery. 2004 Feb;135(2):149-56
pubmed: 14739849
G Chir. 2018 Jan-Feb;39(1):5-11
pubmed: 29549675
Arch Surg. 1999 Jul;134(7):699-704; discussion 704-5
pubmed: 10401818
Updates Surg. 2017 Jun;69(2):161-169
pubmed: 28434176
Am J Surg. 2019 Jan;217(1):108-113
pubmed: 29980283